expression of the epidermal growth factor receptor (egfr) is frequently associated with malignant transform- ation in carcinomas, including crc (5,6).
There are two anti-EGFR monoclonal antibodies, panitumumab and cetuximab, that are approved in the USA and Europe for the treatment of mCRC.